The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...

A ketogenic diet may improve symptoms of depression, according to a new review and meta-analysis published in JAMA Psychiatry ...

The ketogenic diet significantly improves symptoms in epilepsy, schizophrenia, as well as in alcohol use disorder, opioid use ...

The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...

New findings reported in JAMA Network Open from a longitudinal cohort study utilizing electronic health records (EHRs) show that individuals with a prior serious mental illness (SMI), including ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

If you’re living with bipolar disorder and standard treatments aren’t bringing relief, your provider might use the term “treatment-resistant.” It’s a label that can sound worryingly like “untreatable, ...

Objective: Bipolar disorder (BD) involves complex mood, neuropsychological, immunological, and physiological changes, with cognitive impairment persisting even during remission. Our study investigated ...

Bipolar disorder is a complex mental health condition characterized by a potential breadth of both manic and depressive symptoms, such as a euphoric mood and decreased need for sleep, shifting to loss ...